An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors
Breast - Female | Breast - Male | Breast
What is the purpose of this trial?
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with paclitaxel designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in patients with advanced or metastatic solid tumors.
- Ages18 years and older
- Trial withDeciphera Pharmaceuticals, LLC
- Start Date07/28/2019
- End Date11/10/2020
- Last Updated08/06/2019
- Study HIC#2000023438